HomeBUSINESS
BUSINESS

Alecensa Approved for 1st-Line Treatment of NSCLC in Taiwan: Chugai
(May.17.2018)

Chugai Pharmaceutical said on May 16 that its wholly-owned subsidiary Chugai Pharma Taiwan won approval of its ALK inhibitor Alecensa (alectinib) from the Taiwan Food and Drug Administration (TFDA) for first-line treatment of patients with ALK-positive, advanced non-small cell lung cancer (NSCLC) ...
(LOG IN FOR FULL STORY)